HC Wainwright Has Positive Outlook for SPRB FY2025 Earnings

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Equities researchers at HC Wainwright raised their FY2025 earnings estimates for shares of Spruce Biosciences in a note issued to investors on Thursday, February 19th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($55.59) per share for the year, up from their prior estimate of ($57.15). HC Wainwright currently has a “Buy” rating and a $200.00 price target on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q4 2025 earnings at ($13.73) EPS, Q1 2026 earnings at ($10.46) EPS, Q2 2026 earnings at ($9.38) EPS, Q4 2026 earnings at ($9.31) EPS and FY2026 earnings at ($38.23) EPS.

A number of other research firms have also recently commented on SPRB. Wall Street Zen cut shares of Spruce Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, December 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Spruce Biosciences in a research note on Monday, December 29th. Citigroup reaffirmed a “market perform” rating on shares of Spruce Biosciences in a research report on Tuesday, November 11th. Citizens Jmp set a $259.00 price objective on Spruce Biosciences in a report on Tuesday, November 11th. Finally, Leerink Partners upgraded Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $160.00 price objective on the stock in a research note on Wednesday, December 3rd. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $187.90.

Spruce Biosciences Stock Down 5.5%

SPRB opened at $49.72 on Monday. Spruce Biosciences has a twelve month low of $4.28 and a twelve month high of $240.00. The company’s 50-day moving average price is $77.55 and its two-hundred day moving average price is $71.87. The stock has a market cap of $53.20 million, a price-to-earnings ratio of -0.58 and a beta of 3.52.

Institutional Trading of Spruce Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Carlyle Group Inc. bought a new position in shares of Spruce Biosciences in the third quarter valued at approximately $24,765,000. Boothbay Fund Management LLC bought a new stake in Spruce Biosciences during the 4th quarter worth approximately $4,175,000. Caligan Partners LP purchased a new stake in Spruce Biosciences in the 4th quarter worth approximately $1,787,000. ADAR1 Capital Management LLC bought a new position in Spruce Biosciences in the 4th quarter valued at $5,052,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in Spruce Biosciences in the 4th quarter valued at $2,157,000. Hedge funds and other institutional investors own 91.71% of the company’s stock.

About Spruce Biosciences

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.